This is a multicenter prospective observational study that included a large cohort (n = 397) of allogeneic (allo-HSCT; (n = 311) and autologous (ASCT) hematopoietic stem cell transplant (n = 86) recipients who were monitored for antibody detection within 3–6 weeks after complete severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination from February 1, 2021, to July 20, 2021. Most patients (n = 387, 97.4%) received mRNA-based vaccines. Most of the recipients (93%) were vaccinated more than 1 year after transplant. Detectable SARS-CoV-2-reactive antibodies were observed in 242 (78%) of allo-HSCT and in 73 (85%) of ASCT recipients. Multivariate analysis in allo-HSCT recipients identified lymphopenia < 1 × 10⁹/ml (odds ratio [OR] 0.33, 95% confidence interval [95% CI] 0.16–0.69, p = .003), active graft versus host disease (GvHD; OR 0.51, 95% CI 0.27–0.98, p = .04) and vaccination within the first year of transplant (OR 0.3, 95% CI 0.15–0.9, p = .04) associated with lower antibody detection whereas. In ASCT, non-Hodgkin's lymphoma (NHL; OR 0.09, 95% CI 0.02–0.44, p = .003) and active corticosteroid therapy (OR 0.2, 95% CI 0.02–0.87, p = .03) were associated with lower detection rate. We report an encouraging rate of SARS-CoV-2-reactive antibodies detection in these severe immunocompromised patients. Lymphopenia, GvHD, the timing of vaccine, and NHL and corticosteroids therapy should be considered in allo-HSCT and ASCT, respectively, to identify candidates for SARS-CoV-2 antibodies monitoring.

中文翻译：

---

造血干细胞移植受者接种 SARS-CoV-2 疫苗后 SARS-CoV-2 反应性抗体检测：西班牙造血干细胞移植和细胞治疗小组的前瞻性调查

这是一项多中心前瞻性观察性研究，包括一个大队列 ( n  = 397) 的同种异体 (allo-HSCT; ( n  = 311) 和自体 (ASCT) 造血干细胞移植 ( n  = 86) 受者，并接受抗体检测监测从 2021 年 2 月 1 日到 2021 年 7 月 20 日，在完成严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗接种后的 3-6 周内。大多数患者 ( n  = 387, 97.4%) 接受了基于 mRNA 的疫苗。的受者 (93%) 在移植后 1 年以上接种疫苗。在 242 名 (78%) 的 allo-HSCT 和 73 名 (85%) 的 ASCT 受者中观察到可检测到的 SARS-CoV-2 反应性抗体。多变量分析在 allo-HSCT 受者中发现淋巴细胞减少 < 1 × 10⁹ /ml（优势比 [OR] 0.33, 95% 置信区间 [95% CI] 0.16–0.69, p  = .003），活动性移植物抗宿主病 (GvHD; OR 0.51, 95% CI 0.27–0.98, p  = .04) 和移植第一年内接种疫苗 (OR 0.3, 95% CI 0.15–0.9, p  = .04) 与较低的抗体检测相关。在 ASCT 中，非霍奇金淋巴瘤 (NHL; OR 0.09, 95% CI 0.02–0.44, p  = .003) 和活性皮质类固醇治疗 (OR 0.2, 95% CI 0.02–0.87, p = .03) 与较低的检出率相关。我们报告了在这些严重的免疫功能低下患者中检测到 SARS-CoV-2 反应性抗体的令人鼓舞的比率。在 allo-HSCT 和 ASCT 中应分别考虑淋巴细胞减少、GvHD、疫苗接种时机以及 NHL 和皮质类固醇治疗，以确定 SARS-CoV-2 抗体监测的候选者。